Alzheimer's Disease
2 clinical trials enrolling >40 patients indicate that MSC treatment might have a positive impact on biomarkers with both studies also meeting their primary safety endpoints
Key Insights
Effect on biomarkers: Fluid-based and imaging biomarkers indicated significant improvement in the MSC arms versus placebo.
Clinical Potential: Larger studies are required and are on their way to investigate the efficacy of treatment.
Safety: The safety endpoints in the two studies were met.